Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials - The Journal of Allergy and Clinical Immunology: In Practice
Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation - Respiratory Medicine
Teva files MAA for asthma treatment reslizumab
Upcoming Reslizumab PDUFA- Approval Odds, And What It Means For Teva (NYSE: TEVA) | Seeking Alpha
Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
Israeli Pharma gets FDA Approval for Asthma Antibody
Teva announces FDA approval for asthma injection, Cinqair | Pharmafile
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
NICE changes mind and backs new drug for severe asthma | Nursing Times
Reslizumab Reslizumab (Teva) | Bioz | Ratings For Life-Science Research
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
cinqaero - Twitter Search / Twitter
Injectable asthma drug reslizumab approved by European Commission - The Pharmaceutical Journal
Dosing and Administration
Reslizumab – All About Drugs
BUY Reslizumab (CINQAIR) 10 mg/mL Teva Respiratory, LLC
A Guide to the PRESCRIPTION AND SERVICE REQUEST FORM FOR CINQAIR® ( reslizumab) Injection
Reslizumab
Reslizumab - wikidoc
Cinqair (reslizumab): Basics, Side Effects & Reviews
A Guide to the Prescription and Service Request Form
Subcutaneous Cinqair results add to Teva's troubles
Reslizumab | New Drug Approvals
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison - Journal of Allergy and Clinical Immunology
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
